Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.